Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Creatine Monohydrate Supplementation | Experimental | Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. |
|
| Placebo Supplementation | Placebo Comparator | Participants will receive 5 grams of a placebo powder (maltodextrin), visually identical and similarly flavored to the creatine supplement, 30 minutes before sleep each night for 7 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Creatine Monohydrate | Dietary Supplement | Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Average Power Output (Watts) - 30-Second Wingate Test | Average anaerobic power output will be calculated across the 30-second Wingate cycling test. | Baseline and post-intervention (Day 0 and Day 7) |
| Measure | Description | Time Frame |
|---|---|---|
| Peak Power Output (Watts) - Wingate Test | Peak power output during the initial 5 seconds of the 30-second Wingate cycling test. | Baseline and post-intervention (Day 0 and Day 7) |
| Fatigue Index (%) - Wingate Test |
Not provided
Inclusion Criteria:
Female, aged 18 to 25 years
Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)
Regular menstrual cycles (used for scheduling purposes)
Able and willing to provide informed consent
Agreement to maintain normal diet and training routines throughout the study
Exclusion Criteria:
History of musculoskeletal injury affecting lower or upper limbs within the past 6 months
Known allergy or intolerance to creatine or maltodextrin
Use of performance-enhancing substances or supplements within the last 30 days
Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period
Current use of anti-inflammatory medication
Pregnancy or breastfeeding
Inability to comply with study protocol or scheduled assessments
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Morteza Jourkesh, PhD | Contact | +98 938 278 4093 | mjourkesh@iau.ac.ir | |
| Caglar Soylu, phD | Contact | +90 5078593595 | fztcaglar5187@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Islamic Azad University, Shabestar Branch | Recruiting | Shabestar | East Azerbaijan Province | 5381637183 | Iran |
The individual participant data (IPD) will not be shared due to privacy concerns and the limited scope of this study. The study involves a small sample size, and data sharing could risk participant confidentiality. Additionally, there are currently no external collaborations or repositories arranged for data sharing.
Not provided
Not provided
Not provided
Not provided
Not provided
Participants are randomly assigned to one of two groups: a creatine supplementation group or a placebo group, and they remain in that group for the duration of the trial.
Not provided
Not provided
Neither the participants nor the investigators know which intervention the participant is receiving.
Not provided
| Placebo (Maltodextrin) | Dietary Supplement | Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days. |
|
Calculated as the percent drop in power from peak to minimum power output during the 30-second Wingate test, indicating fatigue rate.
| Baseline and post-intervention (Day 0 and Day 7) |
| Serum Creatine Kinase (CK) Activity | Serum creatine kinase activity will be measured as a marker of muscle damage using a spectrophotometric assay. | Baseline and 24 hours post Wingate Test (Day 0 and Day 8) |
| Serum Lactate Dehydrogenase (LDH) Activity | Serum lactate dehydrogenase activity will be measured as an indicator of cell membrane permeability and muscle damage using spectrophotometry. | Baseline and 24 hours post Wingate Test (Day 0 and Day 8) |
| ID | Term |
|---|---|
| D003401 | Creatine |
| C008315 | maltodextrin |
| ID | Term |
|---|---|
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided